Reporting owner · CIK 0001672659

Rodman David Malcom

Visual SEC Form 4 history across 1 companies, 56 transactions and 8 filings.

CMOChief Medical OfficerMineralys Therapeutics, Inc.
Open-market mix
Latest filingFeb 14, 2026, 12:25 AM
Filings8Form 4 records
Buying$00 purchases
Selling$10.8M13 sales
Net value−$10.8MBuys minus sells
Companies12 securities
Most recentFeb 13, 2026exercise

Latest insider transactions

Form 4 filings from available history. Click any column to sort; click it again to flip the order.

Rodman David Malcom transactions
IDTickerInsiderRoleTypeSharesValueCodeFiledTrans date
#73865MLYSRodman David Malcom
CMO
exercise10b5-14.16k$0M02/1402/13
#73864MLYSRodman David Malcom
CMO
exercise10b5-13.54k$0M02/1402/13
#73863MLYSRodman David Malcom
CMO
exercise10b5-16.34k$0M02/1402/12
#73862MLYSRodman David Malcom
CMO
sale10b5-16.34k-$17.5MS02/1402/13
#73861MLYSRodman David Malcom
CMO
sale10b5-14.16k-$11.3MS02/1402/13
#73860MLYSRodman David Malcom
CMO
exercise10b5-14.16k$5.93MM02/1402/13
#73859MLYSRodman David Malcom
CMO
sale10b5-13.54k-$9.67MS02/1402/13
#73858MLYSRodman David Malcom
CMO
exercise10b5-13.54k$3.61MM02/1402/13
#73857MLYSRodman David Malcom
CMO
sale10b5-1521-$1.54MS02/1402/12
#73856MLYSRodman David Malcom
CMO
sale10b5-15.82k-$16.8MS02/1402/12

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Mineralys Therapeutics, Inc. on Feb 13, 2026 valued at $175,100.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Mineralys Therapeutics, Inc. on Feb 13, 2026 valued at $175,100.

Review SEC filing

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

34 observations · Jan 13, 2025 – Feb 13, 2026. Window ends at the latest available report, not today.

Selected observation · Feb 13, 202644,089 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Jan 13, 2025151,823Jan 16, 2025View transaction
Jan 13, 2025158,172Jan 16, 2025View transaction
Feb 12, 2025164,520Feb 13, 2025View transaction
Jan 2, 202681,888Jan 7, 2026View transaction
Jan 2, 202685,517Jan 7, 2026View transaction
Jan 2, 202694,864Jan 7, 2026View transaction
Jan 2, 2026115,032Jan 7, 2026View transaction
Jan 2, 2026139,225Jan 7, 2026View transaction
Jan 2, 202669,188Jan 7, 2026View transaction
Jan 5, 202697,226Jan 7, 2026View transaction
Jan 5, 2026107,347Jan 7, 2026View transaction
Jan 5, 2026133,416Jan 7, 2026View transaction
Jan 5, 2026187,046Jan 7, 2026View transaction
Jan 5, 2026254,519Jan 7, 2026View transaction
Jan 5, 2026115,274Jan 7, 2026View transaction
Jan 5, 202661,804Jan 7, 2026View transaction
Jan 9, 202663,974Jan 14, 2026View transaction
Jan 9, 202661,804Jan 14, 2026View transaction
Jan 12, 202668,152Jan 14, 2026View transaction
Jan 12, 202661,804Jan 14, 2026View transaction
Jan 13, 202665,346Jan 16, 2026View transaction
Jan 13, 202669,513Jan 16, 2026View transaction
Jan 13, 202661,804Jan 16, 2026View transaction
Jan 14, 202650,437Jan 16, 2026View transaction
Feb 9, 202652,608Feb 11, 2026View transaction
Feb 9, 202650,437Feb 11, 2026View transaction
Feb 12, 202656,786Feb 14, 2026View transaction
Feb 12, 202650,958Feb 14, 2026View transaction
Feb 12, 202650,437Feb 14, 2026View transaction
Feb 13, 202653,978Feb 14, 2026View transaction
Feb 13, 202650,437Feb 14, 2026View transaction
Feb 13, 202654,603Feb 14, 2026View transaction
Feb 13, 202650,437Feb 14, 2026View transaction
Feb 13, 202644,089Feb 14, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
1050-5-10Jan 25Feb 257Jan 266Feb 26

Net value flow

Buys minus sells

Jan 25
$0
Feb 25
$0
Jan 26
−$10.2M
Feb 26
−$635.4K

Transaction texture

Ownership and ticket size

Average P/S size$830.5K
Median P/S size$175.1K
Direct56
Indirect0
Feb 13, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Delayed Filingfiling-context1Derivative Transactionfiling-context18Direct Ownershipfiling-context44Large Holdings Increaseholdings4Large Holdings Reductionholdings7Large Salesize3Repeat Sellerpattern710b5-1 Detectedfiling-context37

Associated companies

Visual map of known reporting history

Mineralys Therapeutics, Inc.MLYS · 56 transactions · latest Feb 14, 2026, 12:25 AM

Rodman David Malcom Insider Activity FAQ

SEC Form 4 context

Who is Rodman David Malcom?

Rodman David Malcom is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001672659.

Which companies has Rodman David Malcom reported transactions for?

Mineralys Therapeutics, Inc.

When was Rodman David Malcom's latest insider buy?

No open-market insider purchase is available for this period.

When was Rodman David Malcom's latest insider sale?

sale at Mineralys Therapeutics, Inc. on Feb 13, 2026 valued at $175,100.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.